Stay updated with breaking news from Reshape Lifescience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ReShape Lifesciences reported that it gained approval from the United States Patent and Trademark Office for its application entitled, "Intragastric Device (For Treating Obesity)." In the patent filings, the company described the product as a swallowable implant that expands via a balloon in the stomach to induce a feeling of fullness, helping to restrict food intake.
Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and ReShape Lifesciences (NASDAQ:RSLS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Profitability This table compares Vivos Therapeutics and […]
Michael Miller: Good afternoon, and thank you for joining the ReShape Lifesciences third quarter 2023 earnings call.
Michael Miller: Good afternoon, and thank you for joining the ReShape Lifesciences second quarter 2023 earnings call.
Sigyn Therapeutics (OTCMKTS:SIGY – Get Rating) and ReShape Lifesciences (OTCMKTS:RSLS – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Volatility & Risk Sigyn Therapeutics has a beta of […]